ExodusPoint Capital Management’s Ginkgo Bioworks DNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DNA
ExodusPoint Capital Management's DNA Position: Q3 2026 in Review
ExodusPoint Capital Management sold out of Ginkgo Bioworks (DNA) in Q3 2026, closing a stake of 14,969 shares — an estimated $148K sold.
ExodusPoint Capital Management first reported a position in DNA in Q4 2021 and held it in 8 quarters. The position peaked at $3.11M in Q1 2022. 185 funds tracked by Wall St. Rank hold DNA as of Q3 2026.
- ExodusPoint Capital Management reported no remaining Ginkgo Bioworks position as of Q3 2026 after selling out during the quarter.
- ExodusPoint Capital Management sold 14,969 Ginkgo Bioworks shares in Q3 2026, an estimated $148K.
- ExodusPoint Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 8 quarters.
- ExodusPoint Capital Management's Ginkgo Bioworks position peaked at $3.11M in Q1 2022.
- 185 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.
Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.